Effects of CB1 receptor negative allosteric modulator Org27569 on oxycodone withdrawal symptoms in mice.

Rationale/objectives: Targeting cannabinoid receptor type 1 (CB1R) has shown promise for treating opioid withdrawal symptoms. This study aimed to investigate the efficacy of a specific CB1R negative allosteric modulator (NAM), Org27569, in reducing both naloxone-precipitated and protracted withdrawal symptoms in oxycodone-dependent mice.

Methods: Mice received escalating doses of oxycodone (9-33 mg/kg IP) or saline twice daily for 9 days, followed by a final dose of oxycodone (33 mg/kg) or saline in the morning of day 9.

Sex differences in recovery from cognitive and metabolic impairments induced by supplementary sucrose in rats.

Consumption of beverages containing around 10% sucrose contributes to worldwide obesity. Studies using rats can increase understanding of the consequences of such consumption. The present experiment aimed to compare male and female rats, first, in terms of cognitive and metabolic impairments produced by excessive intakes of 10% sucrose solution (Stage 1:8 weeks) and, second, with regard to recovery once access to sucrose ceased (Stage 2:4 weeks).